Skip to main content

Market Overview

Recap: NeoGenomics Q4 Earnings



Shares of NeoGenomics (NASDAQ:NEO) were unchanged after the company reported Q4 results.

Quarterly Results

Earnings per share rose 40.00% over the past year to $0.14, which beat the estimate of $0.06.

Revenue of $125,997,000 higher by 17.90% year over year, which beat the estimate of $123,480,000.


NeoGenomics hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Feb 24, 2021

Time: 08:30 AM

ET Webcast URL:

Recent Stock Performance

Company's 52-week high was at $61.57

Company's 52-week low was at $20.47

Price action over last quarter: Up 32.97%

Company Description

NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.


Related Articles (NEO)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at